SpectraCure AB has for four days participated with a stand at Urologiveckan, the annual conference gathering Sweden's top urologists, urology nurses, and researchers. This presence enhances SpectraCure's relationship with leading urologists.

At this year's Urologivecka in Sundsvall, SpectraCure demonstrated the system and highlighted the company's ongoing clinical study. The conference serves as a strategic platform to establish SpectraCure's presence among urologists and raises at the same time awareness of the ongoing clinical study.

“These past four days have been filled with interesting meetings and discussions with urologists and nurses who have shown interest in our method. There is a clear consensus and a desire to explore and develop new focal treatment options for patients affected by recurrent prostate cancer," says Kristina Holst, Head of Clinical Affairs, SpectraCure.

"We can build strong relationships with leading urologists through active participation and visibility in these contexts. This enables us to establish SpectraCure as a trustworthy and reliable player in the industry and also to increase awareness of the ongoing clinical study," says Masoud Khayyami, acting CEO, SpectraCure.

For further information:
Masoud Khayyami, Acting CEO
E-mail: mk@spectracure.com
Website: www.spectracure.com

SpectraCure is developing a treatment system for the elimination of internal solid cancer tumors. We are initially focusing on recurrent prostate cancer, with the hope of being able to treat other cancers such as primary prostate cancer, breast cancer, pancreatic cancer, and head and neck cancer in the future. The approach is based on a proprietary and patented treatment system, Q-PRO®, consisting of a hardware device, a laser unit, which performs PDT treatment and treats the prostate itself, combined with a software device, the patented IDOSE® dose planning platform. The method allows the laser light dose to be controlled so that the tumour is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to make interstitial PDT treatment accurate, precise, safe for every patient. The goal is that in addition to being tumor free, the patient will be able to maintain their quality of life, with limited side effects. We are conducting clinical trials as an important part of the continued development of the company's treatment system. 

The company is listed in the Premier segment of the Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, and trades under the short name SPEC.

Attachments
SpectraCure strengthens presence among urologists